The Patent Finder

A2 Biotherapeutics, Inc.

16 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2040
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for Compositions and Methods for Treating HER2 Positive Cancers (US 11,730,764) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Engineered immune cells with receptor cross-talk (US 11,976,297) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 11,254,726LILRB1-BASED Chimeric Antigen Receptor
In force
 · Medium confidence
In forceMedium confidence
US 11,730,764Compositions and Methods for Treating HER2 Positive Cancers
In force
 · Medium confidence
In forceMedium confidence
US 12,037,377LILRB1-BASED Chimeric Antigen Receptor
In force
 · Medium confidence
In forceMedium confidence
US 12,187,775LILRB1-BASED Chimeric Antigen Receptor
In force
 · Medium confidence
In forceMedium confidence
US 12,195,513LILRB1-BASED Chimeric Antigen Receptor
In force
 · Medium confidence
In forceMedium confidence
US 11,433,100Compositions and Methods for Treating Ceacam Positive Cancers
In force
 · Medium confidence
In forceMedium confidence
US 11,602,543Compositions and Methods for Treating Mesothelin Positive Cancers
In force
 · High confidence
In forceHigh confidence
US 11,602,544Compositions and Methods for Treating Egfr Positive Cancers
In force
 · Medium confidence
In forceMedium confidence
US 12,459,983Engineered immune cells with receptor signal strength modulated by a hinge
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,534,509Engineered Immune Cells with Receptor Cross-Talk
In force
 · Low confidence
In forceLow confidence
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 4 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited